Clinical Azeliragon by Cantex to be used in the treatment...

Azeliragon by Cantex to be used in the treatment of inflammatory lung diseases like COVID-19

-

Cantex hopes to enter a Phase II trial to study the efficacy of Azeliragon in the treatment of Covid-19.

The Office of Technology Department at Harvard University has provided the license to Cantex Pharmaceuticals for Development of Drug Azeliragon for the treatment of inflammatory lung disease.    

Azeliragon is currently in the clinical stage and it works by binding to and inhibiting RAGE protein. When the lung gets infected by a viral or bacterial pathogen, these micro-organisms release molecules called DAMPs which activate RAGE protein. 

Azeliragon prevents the activation of RAGE protein, thereby exerting its anti-inflammatory effect. Currently, it is the only small-molecule antagonist of RAGE protein under observation in human trials.

Azeliragon has been shown to limit the production of pro-inflammatory cytokines like  IL-6, IL-8, IP-10, and RANTES. The research proving this was conducted at a Human Lung Alveolus Chip at the Wyss Institute.

The Human Lung Alveolus is a microfluidic device consisting of blood vessels and air sacs, mimicking the function of a human lung and disease conditions.

Considering the available data, trials of 2nd phase are likely to kickstart by this year to assess Azeliragon in serious COVID patients. 

Moreover, the company is arranging drugs trials to cure other diseases such as steroid-refractory asthma and to assess its reaction in breast cancer patients. 

In the past, Azeliragon was used for Alzheimer’s disease and diabetic nephropathy, where it was proven to be safe in Phase III clinical trials with upward of 2,000 subjects.

 The company’s Chief Executive Officer Stephen Marcus noted “ Thanks to the great work of the scientists at the Wyss Institute, we now have compelling evidence that Azeliragon may have the potential to prevent severe Covid-19 illness in the form of a once-a-day pill.” 

“We’re excited to have the opportunity to conduct clinical trials of Azeliragon for this disease, seeking to bring this groundbreaking therapy to patients to prevent the life-threatening inflammation that is the major cause of hospitalization and death from Covid-19 infection said Stephen Marcus, M. D., CEO of Cantex.

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you